AUROPHARMA

Aurobindo Pharma Limited

One of India's largest generic drugmakers, integrated from APIs to finished dosages

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

aurobindo.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1666.90
Market cap
96,370 Cr
Stock P/E
26.0
P/B
2.56
Dividend yield
0.2%
ROE (FY26)
9.3%
ROCE (FY26)
12.1%
Operating margin (FY26)
15.1%
Debt / equity (FY26)
0.20
OCF / EBITDA (FY26)
80.7%
OCF / EBITDA (3Y)
61.7%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Aurobindo Pharma makes generic medicines, from active pharmaceutical ingredients (APIs) to finished formulations, and sells them mainly to customers in the US, Europe and other overseas markets, alongside a growing biologics and contract-manufacturing business.

Company snapshot

8thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Debt-to-equity of 0.20x — the company is largely funded by its own money, not borrowed funds.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales7,219 Cr7,352 Cr7,580 Cr7,567 Cr7,796 Cr7,979 Cr8,382 Cr7,868 Cr8,286 Cr8,646 Cr8,853 Cr9,150 Cr
Operating expenses (approx.)5,846 Cr5,750 Cr5,907 Cr5,947 Cr6,230 Cr6,401 Cr6,590 Cr6,265 Cr6,608 Cr6,873 Cr7,101 Cr7,269 Cr
EBITDA1,373 Cr1,601 Cr1,673 Cr1,620 Cr1,566 Cr1,578 Cr1,792 Cr1,603 Cr1,678 Cr1,773 Cr1,753 Cr1,881 Cr
OPM %19.0%21.8%22.1%21.4%20.1%19.8%21.4%20.4%20.3%20.5%19.8%20.6%
Other income187 Cr163 Cr136 Cr221 Cr136 Cr157 Cr135 Cr105 Cr121 Cr188 Cr117 Cr264 Cr
Interest68 Cr76 Cr89 Cr111 Cr113 Cr118 Cr115 Cr98 Cr95 Cr93 Cr98 Cr102 Cr
Depreciation418 Cr423 Cr354 Cr404 Cr382 Cr419 Cr444 Cr406 Cr429 Cr465 Cr479 Cr487 Cr
Profit before tax1,076 Cr1,262 Cr1,230 Cr1,324 Cr1,207 Cr1,200 Cr1,335 Cr1,207 Cr1,276 Cr1,339 Cr1,291 Cr1,515 Cr
Tax %30.1%25.5%26.2%30.6%32.3%29.5%32.4%31.7%33.5%32.0%28.7%31.9%
Net profit752 Cr940 Cr907 Cr918 Cr817 Cr846 Cr903 Cr824 Cr848 Cr910 Cr921 Cr1,032 Cr
EPS (₹)₹12.83₹16.04₹15.51₹15.69₹14.00₹14.56₹15.56₹14.20₹14.61₹15.67₹15.86₹17.86

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales15,090 Cr16,500 Cr19,564 Cr23,099 Cr24,775 Cr23,455 Cr24,855 Cr29,002 Cr31,724 Cr33,653 CrSign in free for the trailing twelve months
Operating expenses (approx.)11,656 Cr12,728 Cr15,672 Cr18,274 Cr19,441 Cr19,069 Cr21,137 Cr23,159 Cr25,141 Cr26,807 CrSign in free for the trailing twelve months
EBITDA3,434 Cr3,772 Cr3,892 Cr4,825 Cr5,333 Cr4,387 Cr3,719 Cr5,843 Cr6,583 Cr6,846 CrSign in free for the trailing twelve months
OPM %22.8%22.9%19.9%20.9%21.5%18.7%15.0%20.1%20.8%20.3%Sign in free for the trailing twelve months
Other income116 Cr102 Cr116 Cr86 Cr381 Cr320 Cr291 Cr557 Cr622 Cr492 CrSign in free for the trailing twelve months
Interest67 Cr78 Cr163 Cr160 Cr74 Cr49 Cr140 Cr290 Cr457 Cr384 CrSign in free for the trailing twelve months
Depreciation428 Cr558 Cr668 Cr967 Cr1,055 Cr1,127 Cr1,245 Cr1,522 Cr1,649 Cr1,778 CrSign in free for the trailing twelve months
Profit before tax3,061 Cr3,241 Cr3,091 Cr3,743 Cr7,344 Cr3,373 Cr2,613 Cr4,380 Cr5,066 Cr5,112 CrSign in free for the trailing twelve months
Tax %24.8%25.2%23.5%24.4%27.4%21.5%26.2%27.6%31.2%31.5%Sign in free for the trailing twelve months
Net profit2,302 Cr2,423 Cr2,365 Cr2,830 Cr5,334 Cr2,647 Cr1,928 Cr3,169 Cr3,484 Cr3,503 CrSign in free for the trailing twelve months
EPS (₹)₹39.33₹41.36₹40.36₹48.32₹91.04₹45.19₹32.90₹54.16₹59.81₹60.34Sign in free for the trailing twelve months
Dividend payout %————4.4%10.0%22.8%8.3%0.0%6.6%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital59 Cr59 Cr59 Cr59 Cr59 Cr59 Cr59 Cr59 Cr58 Cr58 Cr
Reserves9,313 Cr11,622 Cr13,832 Cr16,752 Cr21,871 Cr24,517 Cr26,781 Cr29,784 Cr32,595 Cr37,833 Cr
Borrowings3,084 Cr4,483 Cr6,753 Cr5,422 Cr4,971 Cr2,373 Cr4,862 Cr6,315 Cr7,942 Cr7,676 Cr
Other liabilities3,791 Cr4,940 Cr5,809 Cr6,694 Cr6,954 Cr6,975 Cr8,177 Cr8,905 Cr9,196 Cr12,943 Cr
Total liabilities16,249 Cr21,105 Cr26,454 Cr28,926 Cr33,854 Cr33,922 Cr39,890 Cr45,072 Cr49,785 Cr58,502 Cr
Fixed assets (net)4,083 Cr4,737 Cr5,694 Cr6,495 Cr6,887 Cr7,728 Cr7,995 Cr11,546 Cr12,189 Cr14,330 Cr
CWIP1,237 Cr1,400 Cr1,342 Cr1,622 Cr2,429 Cr2,938 Cr4,496 Cr2,739 Cr3,266 Cr3,009 Cr
Investments246 Cr312 Cr360 Cr555 Cr591 Cr997 Cr543 Cr372 Cr252 Cr1,051 Cr
Loans & advances——10 Cr14 Cr14 Cr13 Cr12 Cr13 Cr16 Cr18 Cr
Inventories4,331 Cr5,858 Cr7,246 Cr7,700 Cr9,027 Cr7,554 Cr8,511 Cr9,808 Cr10,544 Cr12,053 Cr
Trade receivables2,765 Cr3,084 Cr3,414 Cr4,315 Cr3,503 Cr4,012 Cr4,466 Cr4,817 Cr5,746 Cr7,094 Cr
Cash & bank489 Cr1,216 Cr1,886 Cr2,764 Cr5,373 Cr4,163 Cr4,396 Cr3,393 Cr5,569 Cr7,191 Cr
Other assets3,098 Cr4,499 Cr6,503 Cr5,463 Cr6,030 Cr6,517 Cr9,469 Cr12,383 Cr12,204 Cr13,756 Cr
Total assets16,249 Cr21,105 Cr26,454 Cr28,926 Cr33,854 Cr33,922 Cr39,890 Cr45,072 Cr49,785 Cr58,502 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity3,279 Cr1,955 Cr1,651 Cr4,381 Cr3,329 Cr5,016 Cr2,387 Cr2,435 Cr3,925 Cr5,526 Cr
Cash from investing-1,787 Cr-1,957 Cr-2,903 Cr-1,568 Cr599 Cr-3,215 Cr-3,978 Cr-4,256 Cr-1,875 Cr-3,458 Cr
Cash from financing-1,915 Cr864 Cr1,919 Cr-1,947 Cr-1,365 Cr-2,969 Cr1,814 Cr800 Cr120 Cr-1,269 Cr
Net cash flow-424 Cr862 Cr667 Cr866 Cr2,583 Cr-1,167 Cr223 Cr-1,007 Cr2,178 Cr1,628 Cr
Free cash flow (OCF − Capex)1,584 Cr425 Cr92 Cr2,950 Cr1,455 Cr2,312 Cr-334 Cr-1,127 Cr1,405 Cr2,422 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %25.1%20.5%15.8%17.6%27.6%12.7%8.7%12.9%13.6%12.1%
ROE %24.6%20.7%17.0%16.8%24.3%10.8%7.2%10.6%10.7%9.3%
Debtor days67686468516265616677
Inventory days304379354364395373321332357426
Days payable151170131120122133146151142197
Cash conversion cycle219277287312324302240242281306
OCF / EBITDA %95.5%51.8%42.4%90.8%62.4%114.4%64.2%41.7%59.6%80.7%
OCF / EBITDA % (3 years)——62.0%64.0%66.6%87.5%79.9%70.5%54.2%61.7%
Debt / equity0.330.380.490.320.230.100.180.210.240.20
Current ratio1.391.401.281.441.852.211.871.951.851.81
Net debt / EBITDA0.76—1.250.55-0.08-0.410.130.500.360.07